The polycomb group protein enhancer of zeste homolog 2 (EZH 2) is an oncogene that influences myeloma cell growth and the mutant ras phenotype.
about
Differential release of chromatin-bound IL-1alpha discriminates between necrotic and apoptotic cell death by the ability to induce sterile inflammationEZH2 in normal hematopoiesis and hematological malignanciesHost epigenetic modifications by oncogenic virusesNovel therapeutic strategies for multiple myelomaDiverse involvement of EZH2 in cancer epigeneticsThe Polycomb group protein EZH2 impairs DNA repair in breast epithelial cellsOncogenic RAS directs silencing of tumor suppressor genes through ordered recruitment of transcriptional repressorsDeazaneplanocin a is a promising drug to kill multiple myeloma cells in their nichePolycomb target genes are silenced in multiple myeloma.Enhancer of zeste homolog 2 (EZH2) expression is an independent prognostic factor in renal cell carcinomaDown-regulation of miR-101 in endothelial cells promotes blood vessel formation through reduced repression of EZH2The miR-125a and miR-320c are potential tumor suppressor microRNAs epigenetically silenced by the polycomb repressive complex 2 in multiple myelomaThe role of epigenetics in aging and autoimmunity.Histone methyltransferase MMSET/NSD2 alters EZH2 binding and reprograms the myeloma epigenome through global and focal changes in H3K36 and H3K27 methylationEpigenetic antagonism between polycomb and SWI/SNF complexes during oncogenic transformationEnhancer of Zeste homolog 2 (EZH2) is overexpressed in recurrent nasopharyngeal carcinoma and is regulated by miR-26a, miR-101, and miR-98.In utero exposure to diethylstilbestrol (DES) or bisphenol-A (BPA) increases EZH2 expression in the mammary gland: an epigenetic mechanism linking endocrine disruptors to breast cancerCancer epigenetics: linking basic biology to clinical medicine.Histone methylases as novel drug targets: developing inhibitors of EZH2.Connections between epigenetic gene silencing and human disease.Polycomb repressive complex 2 is required for MLL-AF9 leukemiaHistone demethylases and cancer.A systematic analysis of miRNA transcriptome in Marek's disease virus-induced lymphoma reveals novel and differentially expressed miRNAs.Inhibition of EZH2 suppresses self-renewal and induces radiation sensitivity in atypical rhabdoid teratoid tumor cells.Targeting EZH2-mediated methylation of H3K27 inhibits proliferation and migration of Synovial Sarcoma in vitroGenome-wide profiling of histone H3 lysine 27 and lysine 4 trimethylation in multiple myeloma reveals the importance of Polycomb gene targeting and highlights EZH2 as a potential therapeutic target.Epigenetic silencing of CCAAT/enhancer-binding protein delta activity by YY1/polycomb group/DNA methyltransferase complex.Epigenetics, aging, and autoimmunity.Genomic loss of microRNA-101 leads to overexpression of histone methyltransferase EZH2 in cancer.Polycomb group protein enhancer of zeste 2 is an oncogene that promotes the neoplastic transformation of a benign prostatic epithelial cell lineSTAT3 signaling drives EZH2 transcriptional activation and mediates poor prognosis in gastric cancer.Polycomb group protein gene silencing, non-coding RNA, stem cells, and cancer.EZH2 inhibition in multiple myeloma downregulates myeloma associated oncogenes and upregulates microRNAs with potential tumor suppressor functions.Blocking EZH2 methylation transferase activity by GSK126 decreases stem cell-like myeloma cells.Epigenetics of estrogen receptor signaling: role in hormonal cancer progression and therapy.The role of epigenetics in the biology of multiple myeloma.Current and potential epigenetic targets in multiple myeloma.In silico and experimental analyses predict the therapeutic value of an EZH2 inhibitor GSK343 against hepatocellular carcinoma through the induction of metallothionein genes.Driver mutations of cancer epigenomes.Targeting Intrinsic and Extrinsic Vulnerabilities for the Treatment of Multiple Myeloma.
P2860
Q24646390-3CE887F2-86CA-4523-A044-BABD2FC2830AQ26779821-FE41E77C-3C2B-46DC-B946-DD0B4786E7BAQ27485909-1280ED92-1BAA-46D1-8E9B-71D530747A54Q28081590-09BE39D7-B168-49C8-8F2A-F045A17FEC81Q28084911-CD8BF907-D770-4968-A2B0-DBD0A2CA8E93Q28285316-4F130813-F0AE-48B1-A496-B821C728B999Q28510632-F0B9A614-CC4C-440B-BC41-1892CFE6DE66Q28543228-042CC62C-DC8F-4B1A-959F-87F5ED6F83B0Q33633898-0A3A2967-0D4F-4F99-86B4-5A5A085271BAQ33710169-264D5AA9-BB75-4626-9E16-879070E623ABQ33813030-A1553842-5D84-41E0-A7CF-5176F7102DB8Q33838260-5599266E-A584-4AF2-B142-C675F8CFC149Q33927921-B6E5AEAD-C21E-4B7B-98DB-6D3434BB1222Q34133622-5585BBA6-4C7A-459B-A7AD-5A96F49EECAFQ34213023-27BEA5BB-52E4-4D39-BCE9-64457C59E614Q34561758-54A4F430-068E-4EE0-B43C-45D87B08F50CQ35116862-693F24C2-2F83-435C-95E3-62B7CC8F70B1Q35348043-05B9D62C-0F92-4B8B-8C4C-CB8B1FB7AF5AQ35510392-D3E36515-A0BF-4D14-BA23-C04B173BD3EBQ35843804-F3F8EB76-80CD-4B7D-B974-BA32AB9EDCCDQ35882496-799FDC5C-FE09-4466-A8F2-E0A054A0D9FAQ36421138-11CA3DEF-733D-4C68-BCFC-2F11BE88DBF9Q36437698-B29CCBFF-74BD-48A0-A323-32D1486DD648Q36544065-81986453-1D38-49D4-8956-125847BDD42FQ36850467-4CA8728D-66DC-420C-A40A-F77107C41DD6Q36916348-11A0989A-791C-4551-9ACE-AB6D81136960Q37142723-B2339813-0903-45A4-985B-84E213D59982Q37146128-ACF86284-B001-4392-9C8A-1E6572CE7FD3Q37198891-F2F1E7D3-93AB-432F-A80C-139BF56AFD5AQ37478998-53C4E84A-FD0A-492B-BDF7-F860AAA9FF10Q37491122-2925D6DF-A070-4721-B508-386FA4B4EB96Q37629613-F5593AC5-70D6-48FE-AEC3-0EEF5BA6CF9AQ37705811-D162A11B-FAE4-4057-8BAC-C37C7781F2EBQ37709478-AA779634-726E-42A2-9ABC-04815890B11CQ37911312-0B06BC68-84D7-4CAC-87B6-6CCADE38BB67Q38208520-3412086A-6B27-4B87-AA08-B19B43145C80Q38210475-4CDCC170-59C0-4771-938C-EA5CC80B0AA8Q38388649-EB0064A5-8AB1-4A24-9A81-84EFEF200BFFQ38639828-31A98E3D-5CD1-40E0-B62B-527D633860EDQ38853857-712AD839-7967-483B-A64E-AA6196496A22
P2860
The polycomb group protein enhancer of zeste homolog 2 (EZH 2) is an oncogene that influences myeloma cell growth and the mutant ras phenotype.
description
2005 nî lūn-bûn
@nan
2005年の論文
@ja
2005年論文
@yue
2005年論文
@zh-hant
2005年論文
@zh-hk
2005年論文
@zh-mo
2005年論文
@zh-tw
2005年论文
@wuu
2005年论文
@zh
2005年论文
@zh-cn
name
The polycomb group protein enh ...... and the mutant ras phenotype.
@en
The polycomb group protein enhancer of zeste homolog 2
@nl
type
label
The polycomb group protein enh ...... and the mutant ras phenotype.
@en
The polycomb group protein enhancer of zeste homolog 2
@nl
prefLabel
The polycomb group protein enh ...... and the mutant ras phenotype.
@en
The polycomb group protein enhancer of zeste homolog 2
@nl
P2860
P356
P1433
P1476
The polycomb group protein enh ...... and the mutant ras phenotype.
@en
P2093
Brian Van Ness
Paula A Croonquist
P2860
P2888
P304
P356
10.1038/SJ.ONC.1208771
P407
P577
2005-09-01T00:00:00Z
P5875
P6179
1019233340